Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10618417 | 0.86 | GABRA1 (0.38) | ALDH1A1APOBEC3GGABRA1GABRB2GABRG2 | |
| SCHEMBL4275363 | 0.81 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL29568735 | 0.80 | ALDH1A1 (0.44) | ALDH1A1APOBEC3GGABRA1GABRB2PDCD1 | |
| SCHEMBL93849 | 0.80 | ALDH1A1 (0.44) | ALDH1A1APOBEC3GGABRA1GABRB2PDCD1 | |
| SCHEMBL2651603 | 0.79 | APOBEC3G (0.34) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL487089 | 0.79 | PDXK (0.37) | ALDH1A1APOBEC3GGABRA1GABRB2PDCD1 | |
| SCHEMBL8955156 | 0.79 | MEN1 (0.42) | ALDH1A1APOBEC3GGABRA1GABRG2GABRB3 | |
| SCHEMBL4589782 | 0.79 | GCGR (0.38) | ALDH1A1APOBEC3GGABRA1GABRB2PDCD1 | |
| SCHEMBL29284833 | 0.78 | ALDH1A1 (0.43) | ALDH1A1APOBEC3GGABRA1GABRB2PDCD1 | |
| SCHEMBL16950434 | 0.78 | PDCD1 (0.48) | ALDH1A1APOBEC3GGABRA1GABRB2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 727 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| US-11633495-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| EP-4056594-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | Birdie Biopharmaceuticals Inc. (KY) | 2022-09-14 | — | — | EP | claimed |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-12 | — | — | US | claimed |
| US-20200345860-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-11-05 | — | — | US | claimed |
| US-10780180-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-09-22 | — | — | US | claimed |
| US-10744206-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-08-18 | — | — | US | claimed |
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | claimed |
| US-20190269789-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | claimed |
| US-10328158-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-06-25 | — | — | US | claimed |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | PIERRE FABRE MEDICAMENT (FR) | 2026-05-28 | — | — | US | disclosed |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | ABDERA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4727586-A1 | ANTI-CD5 ANTIBODIES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2004006753-A2 | SGA-72M, A CANCER ASSOCIATED ANTIGEN, AND USES THEREOF | SEATTLE GENETICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003043583-A2 | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES | SEATTLE GENETICS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-10744206-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-11633494-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | H1-10, IGSF11, CD99 | ALDH1A1 2977/4885APOBEC3G 1182/4885GABRA1 1903/4885 |
| US-20200345860-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-11633495-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-20190269789-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | IGF1R, CD44, MUC1 | ALDH1A1 3043/4885APOBEC3G 4726/4885GABRA1 242/4885 |
| US-10328158-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, FCGR1A | ALDH1A1 3825/4885APOBEC3G 86/4885GABRA1 1923/4885 |
| US-10780180-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
| US-20200353093-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | ALDH1A1 1617/4885APOBEC3G 1085/4885GABRA1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.